Combination Therapy with Cediranib, Olaparib, and Durvalumab for Advanced Solid Tumors
(DAPPER Trial)
Trial Summary
What is the purpose of this trial?
This trial tests a combination of medicines to help the immune system fight advanced colorectal, pancreatic, and soft tissue cancers. It aims to see if these new treatments can be more effective for patients whose cancers are hard to treat with standard therapies.
Will I have to stop taking my current medications?
The trial requires a 4-week period without any prior anti-cancer treatments before starting the study. Additionally, if you are taking certain medications that strongly affect liver enzymes (CYP3A inhibitors or inducers), you may need to stop them 1-5 weeks before starting the trial, depending on the specific medication.
What data supports the effectiveness of the drug combination of Cediranib, Olaparib, and Durvalumab for advanced solid tumors?
Research shows that the combination of Cediranib and Olaparib increased progression-free survival (the time during which the cancer does not get worse) in women with recurrent ovarian cancer. Additionally, the combination of Durvalumab with either Olaparib or Cediranib showed promising disease control rates in women's cancers, with some patients experiencing partial responses and stable disease.12345
Is the combination of Cediranib, Olaparib, and Durvalumab safe for humans?
The combination of Cediranib, Olaparib, and Durvalumab has been studied for safety in women with recurrent cancers. No dose-limiting toxicities were found with Durvalumab plus Olaparib, but some adverse events like high blood pressure and fatigue were noted with Cediranib. Overall, the combinations were considered tolerable.12467
What makes the combination therapy with Cediranib, Olaparib, and Durvalumab unique for treating advanced solid tumors?
This combination therapy is unique because it combines three different mechanisms: Cediranib reduces blood vessel growth to tumors, Olaparib increases DNA damage in cancer cells, and Durvalumab boosts the immune system's ability to fight cancer. This multi-faceted approach aims to enhance the overall anti-tumor activity compared to using these drugs individually.12346
Research Team
Lillian Siu, MD
Principal Investigator
Princess Margaret Cancer Centre
Eligibility Criteria
Adults with advanced colorectal cancer, pancreatic adenocarcinoma, or leiomyosarcoma that's not curable and has failed standard therapy can join. They must be willing to use effective contraception, provide tumor tissue samples, have normal organ function, and no recent major surgeries. Excluded are those with certain heart conditions, uncontrolled hypertension or seizures, recent bleeding events or blood transfusions.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive durvalumab intravenously every 4 weeks. Cohort A receives olaparib orally twice a day continuously, while Cohort B receives cediranib orally once a day for 5 consecutive days with 2 days off each week.
Follow-up
Participants are monitored for safety and effectiveness after treatment, including overall response rate, clinical benefit rate, progression-free survival, and overall survival.
Treatment Details
Interventions
- Cediranib
- Durvalumab
- Olaparib
Cediranib is already approved in United States, European Union for the following indications:
- Alveolar soft part sarcoma
- Alveolar soft part sarcoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor
AstraZeneca
Industry Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology